半乳甘露聚糖是福司莫吉匹克斯（APX001）治疗实验性侵袭性肺曲霉病疗效的生物标志物。
Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis.
机构信息
The Lundquist Institute for Biomedical Innovations, Torrance, California, USA.
Amplyx Pharmaceuticals Inc., San Diego, California, USA
出版信息
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01966-19.
Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in conidial equivalents (CE)/g lung tissue after 96 h versus placebo. Changes in GM levels in BAL fluid and serum mirrored reductions in lung CE, with significant decreases seen after 96 h or 72 h for fosmanogepix or posaconazole, respectively ( < 0.02).
在生物样本中检测半乳甘露聚糖（GM）已被证明可以预测唑类和多烯类药物的治疗反应。在侵袭性肺曲霉病的小鼠模型中，与安慰剂相比，福司莫格匹酯或泊沙康唑治疗 96 小时后肺部组织中的分生孢子相当于（CE）/g 减少了约 6-7 个对数级。BAL 液和血清中的 GM 水平变化与肺部 CE 的减少相吻合，福司莫格匹酯或泊沙康唑分别在 96 小时或 72 小时后观察到显著下降（<0.02）。
Zotero 插件